Archive · 21 Jul 2026
ICMR transfers three biomedical technologies for cancer and infectious disease solutions
The Indian Council of Medical Research (ICMR) has given licenses for three important medical technologies to Indian companies.
One technology, called SHetA2, helps treat cervical cancer by targeting only the bad cells and leaving the good ones alone.
The other two technologies are new vaccines that can protect against typhoid and other serious stomach infections.
These technologies were developed by Indian scientists working with international experts.
The goal is to make these treatments affordable and available to more people in India.
This is part of India's effort to create better healthcare solutions using local innovation.
ICMR has licensed three biomedical technologies to domestic pharmaceutical and vaccine makers.
SHetA2 is a novel anti-HPV therapeutic candidate for treating cervical cancer.
Two next-generation vaccine technologies target enteric bacterial infections like typhoid and Shigella.
Technologies were developed through collaboration between Indian and international researchers.
These transfers aim to provide affordable healthcare solutions and strengthen India's biomedical innovation ecosystem.
- Who
- Indian Council of Medical Research (ICMR), Emcure Pharmaceuticals Ltd., Biological E Ltd.
- What
- Transfer of three biomedical technologies for cancer and infectious disease solutions
- When
- Tuesday (specific date not mentioned)
- Where
- New Delhi, India
- Why
- To accelerate the translation of publicly funded research into affordable healthcare solutions and strengthen India's biomedical innovation ecosystem
Advocates for Indigenous Development
Critics of Technology Transfer
Benefits of Indigenous Development
Advocates for Indigenous Development
Advocates argue that these technology transfers will strengthen India's biomedical innovation ecosystem and provide affordable healthcare solutions.
Critics of Technology Transfer
Critics contend that such transfers may lead to monopolies and higher costs in the long run.
Impact on Public Health
Advocates for Indigenous Development
Proponents believe these technologies will significantly improve cancer prevention and infectious disease control in India.
Critics of Technology Transfer
Opponents argue that the benefits may be overstated and that more rigorous clinical trials are needed before widespread implementation.
- Technologies Transferred
- SHetA2, Salmonella typhi vaccine, recombinant vaccine composition
- Recipient Companies
- Emcure Pharmaceuticals Ltd., Biological E Ltd.
- Developers
- ICMR-NICPR, ICMR-NIRBI, Dr. Showket Hussain, Dr. Doris M. Benbrook
- Potential Impact
- Affordable treatment for cervical cancer, improved typhoid and Shigella vaccines
- Innovation Ecosystem
- Supports healthcare technologies from discovery to commercialisation